文献速递心力衰竭与心肌病血脂与心血管预防

FNDC5对亚临床型糖尿病心肌病的诊断价值

[Diagnostic value of FNDC5 in patients with subclinical diabetic cardiomyopathy].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2021-07-24

该观察性研究纳入94例无心血管症状的2型糖尿病患者,按超声心动图和门控心肌灌注显像分为亚临床DCM组与对照组各47例。亚临床DCM组血清FNDC5水平显著低于对照组,FNDC5单因素诊断AUC为0.940,优于年龄、病程、HbA1c及血脂指标;在基础临床变量模型中加入FNDC5后,模型诊断效能由AUC 0.879提升至0.980。

要点

  • 亚临床DCM患者血清FNDC5水平显著低于无心脏 dysfunction 的T2DM患者(P<0.001)。
  • FNDC5单因素诊断亚临床DCM的AUC=0.940(95%CI 0.897~0.982),优于年龄、病程、HbA1c及血脂指标。
  • 基础临床变量模型加入FNDC5后AUC由0.879升至0.980(P<0.001),诊断效能更优。

核心结论

  • 血清FNDC5联合其他相关基础临床资料对亚临床型DCM具有较好的诊断价值,有望成为诊断亚临床型DCM的生物标志物。

研究设计与样本

  • 该研究为观察性研究,入选2018年4月至2019年6月于苏州大学附属第三医院内分泌科入院的无心血管症状的2型糖尿病患者94例。
  • 根据超声心动图检查和门控心肌灌注显像结果将患者分为亚临床型DCM组47例和糖尿病不伴心功能不全组(对照组)47例。
  • 收集入选患者的一般临床资料和血FNDC5水平,采用ROC曲线分析比较不同参数和模型的诊断效能。

主要发现

  • 与对照组比较,亚临床型DCM组患者年龄更大、糖尿病病程更长,TC、TG、LDL-C和HbA1c水平更高(P均<0.05)。
  • 亚临床型DCM组患者外周血FNDC5表达水平明显低于对照组(P<0.001)。
  • FNDC5水平与室间隔e′波速度(r=0.451,P=0.005)、二尖瓣环e′波速度(r=0.291,P<0.001)和E/A比值(r=0.490,P=0.002)呈正相关。
  • FNDC5水平与A值(r=-0.399,P<0.001)、平均E/e′比值(r=-0.490,P<0.001)、三尖瓣峰值流速(r=-0.567,P<0.001)、左心房容积指数(r=-0.491,P<0.001)呈负相关。
  • 单因素ROC分析示FNDC5诊断效能(AUC=0.940,95%CI 0.897~0.982)优于年龄(AUC=0.639,95%CI 0.523~0.752)、糖尿病病程(AUC=0.663,95%CI 0.555~0.772)、HbA1c(AUC=0.740,95%CI 0.638~0.839)、TG(AUC=0.661,95%CI 0.547~0.776)、TC(AUC=0.675,95%CI 0.563~0.788)和LDL-C(AUC=0.644,95%CI 0.532~0.756)。

关键数值与推荐

  • 模型1以是否发生亚临床型DCM为因变量,以年龄、糖尿病病程、TG、TC、LDL-C和HbA1c为自变量构建。
  • 模型2在模型1基础上引入自变量FNDC5构建多因素联合预测模型。
  • 模型2诊断效能优于模型1(AUC分别为0.980和0.879,P<0.001)。
  • 当灵敏度同为0.617时,模型2特异度高于模型1(0.979比0.936);当特异度同为0.532时,模型2灵敏度高于模型1(1.000比0.915)。

临床怎么用

  • 对于无心血管症状的2型糖尿病患者,可考虑检测血清FNDC5水平以辅助识别亚临床型DCM。
  • FNDC5联合年龄、糖尿病病程、HbA1c及血脂等基础临床资料构建的模型可能提高亚临床型DCM的诊断效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To estimate the diagnostic value of fibronectin type Ⅲ-domain containing protein 5 (FNDC5) in subclinical diabetic cardiomyopathy. Methods: A total of 94 patients with type 2 diabetes (T2DM), who were hospitalized from April 2018 to June 2019 in the Third Affiliated Hospital of Soochow University, were enrolled in this study. Patients were divided into T2DM with cardiac dysfunction (subclinical DCM) group (n=47) and T2DM without cardiac dysfunction (non-DCM) group (n=47) according to echocardiography and gated myocardial perfusion imaging results. Basic clinical data and serum FNDC5 level were compared between the two groups. Logistic regression analysis was used to establish predicting models and the diagnostic efficiency of established models was compared by ROC curve analysis. Results: Compared to non-DCM group, patients in subclinical DCM group were older, with longer duration of diabetes, and had higher levels of glycosylated hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) (all P<0.05). Serum FNDC5 level was significantly lower in subclinical DCM group than in non-DCM group (P<0.001). FNDC5 level was positively correlated with ventricular septal e'(r=0.451,P=0.005), mitral valve e'(r=0.291,P<0.001), the ratio of peak early diastolic trans-mitral flow velocity (E) to peak late diastolic trans-mitral flow velocity (A)(r=0.490,P=0.002), while negatively correlated with A(r=-0.399,P<0.001), the average ratio of E/e'(r=-0.490,P<0.001), tricuspid regurgitation velocity(r=-0.567,P<0.001), left atrial volume index(r=-0.491,P<0.001). Univariate ROC analysis showed that the diagnostic efficacy of FNDC5(AUC=0.940,95%CI 0.897-0.982)was superior to age(AUC=0.639,95%CI 0.523-0.752), diabetic duration(AUC=0.663,95%CI 0.555-0.772), HbA1c(AUC=0.740,95%CI 0.638-0.839), TG(AUC=0.661,95%CI 0.547-0.776), TC(AUC=0.675,95%CI 0.563-0.788)and LDL-C(AUC=0.644,95%CI 0.532-0.756). Model 1 was established with subclinical DCM as dependent variable, age, diabetic duration, TG, TC, LDL-C and HbA1c as independent variables. Model 2 was established by adding FNDC5 as independent variable on the basis of model 1. Diagnostic efficacy for subclinical DCM was compared between the two models by ROC analysis. The diagnostic efficiency was better with model 2 (AUC=0.980) than with model 1 (AUC=0.879, P<0.001). When sensitivity was set at 0.617, the specificity of model 2 was higher than that of model 1(0.979 vs. 0.936). When sensitivity was set at 0.532, the sensitivity of model 2 was higher than that of model 1 (1.000 vs. 0.915). Conclusions: Our findings suggest that serum FNDC5 could be used as a novel biomarker for the diagnosis of subclinical DCM. 目的: 探讨Ⅲ型纤维蛋白结构域结合蛋白5(FNDC5)对亚临床型糖尿病心肌病(DCM)的诊断价值。 方法: 该研究为观察性研究。入选2018年4月至2019年6月于苏州大学附属第三医院内分泌科入院的无心血管症状的2型糖尿病患者,根据超声心动图检查和门控心肌灌注显像结果将患者分为亚临床型DCM组和糖尿病不伴心功能不全组(对照组)。收集入选患者的一般临床资料和血FNDC5水平。采用受试者工作特征(ROC)曲线分析比较不同参数和模型的诊断效能。 结果: 研究共入选患者94例,其中亚临床型DCM组47例,对照组47例。与对照组比较,亚临床型DCM组患者年龄更大、糖尿病病程更长、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和糖化血红蛋白(HbA1c)水平更高(P均<0.05)。亚临床型DCM组患者外周血FNDC5表达水平明显低于对照组(P<0.001)。FNDC5水平与亚临床型DCM患者室间隔e′波速度(r=0.451,P=0.005)、二尖瓣环e′波速度(r=0.291,P<0.001)和左心室舒张早期二尖瓣血流速度峰值(E)/二尖瓣心房收缩期血流速度峰值(A)比值呈正相关(r=0.490,P=0.002),而与A值(r=-0.399,P<0.001)、平均E/e′比值(r=-0.490,P<0.001)、三尖瓣峰值流速(r=-0.567,P<0.001)、左心房容积指数(r=-0.491,P<0.001)呈负相关。单因素ROC曲线分析结果显示,FNDC5的诊断效能(AUC=0.940,95%CI 0.897~0.982)优于年龄(AUC=0.639,95%CI 0.523~0.752)、糖尿病病程(AUC=0.663,95%CI 0.555~0.772)、HbA1c(AUC=0.740,95%CI 0.638~0.839)、TG(AUC=0.661,95%CI 0.547~0.776)、TC(AUC=0.675,95%CI 0.563~0.788)和LDL-C(AUC=0.644,95%CI 0.532~0.756)。以是否发生亚临床型DCM作为因变量,以年龄、糖尿病病程、TG、TC、LDL-C和HbA1c作为自变量,构建亚临床型DCM诊断预测模型(模型1),在模型1的基础上引入自变量FNDC5,构建多因素联合预测模型(模型2)。采用ROC曲线比较模型1与模型2的诊断效能,结果示引入FNDC5作为自变量的模型2对于DCM的诊断效能优于模型1(AUC分别为0.980和0.879,P<0.001)。进一步对两个模型的灵敏度和特异度进行比较,发现当灵敏度同为0.617时,模型2的特异度高于模型1(0.979比0.936);当特异度同为0.532时,模型2的灵敏度高于模型1(1.000比0.915)。 结论: FNDC5联合其他相关基础临床资料对亚临床型DCM具有较好的诊断价值,有望成为诊断亚临床型DCM的生物标志物。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qin ZH, Huang XL, Tao LC, et al. [Diagnostic value of FNDC5 in patients with subclinical diabetic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34256436. doi:10.3760/cma.j.cn112148-20200624-00510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。